(AGENPARL) - Roma, 5 Settembre 2024 - (AGENPARL) – gio 05 settembre 2024 Lund, September 5, 2024. Hansa Biopharma today announced that Søren Tulstrup
will participate in a Fireside chat hosted by Douglas Tsao, Managing Director
and Senior Financial Analyst at H.C. Wainwright on Wednesday, September 11 at
8:00 AM EST. Mr. Tsao’s research focuses on biopharmaceuticals and specialty
pharmaceuticals. The company will cover Hansa’s clinical stage programs, recent
performance and upcoming milestones.
Hansa management will be available for meetings at the conference. If you are
interested in meeting with the management team, please contact Hansa Biopharma
To learn more about Hansa Biopharma see the latest Corporate Presentation
here. (https://www.hansabiopharma.com/files/Presentations/2024/Hansa_Corporate_Pr
esentation_July_2024.pdf) The latest investor presentation can be viewed
arnings_Presentation_FINAL.pdf).
–ENDS-
For more information:
Evan Ballantyne, Chief Financial Officer
Stephanie Kenney, VP Global Corporate Affairs
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a
mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. Hansa Biopharma has
developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme
therapy, which has been shown to enable kidney transplantation in highly
sensitized patients. Hansa Biopharma has a rich and expanding research and
development program based on the Company’s proprietary IgG-cleaving enzyme
technology platform, to address serious unmet medical needs in transplantation,
autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund,
Sweden, and has operations in Europe and the U.S. The company is listed on
Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com
and follow us on LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/2B1nD5zysiqXMFuTWX68D4QGzdqZGVqCRUJttjHne5h9CYbeGyu9W8d4b9CdGgBuF6ng2vXbsSXb749K7NP2MaRyYmUEeXhpFiUvdaeeVyCX7g.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/2B1nD5zysiqXMFuTWX68D4QGzdqZGVqCRUJttjHne5h9CYbeGyu9W8d4b9CdGgBuF6ng2vXbsSXb749K7NP2MaRyYmUEeXhpFiUvdaeeVyCX7g.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content
Trending
- SAISON CULTURELLE 2026/2027 – Musica, comicità e opera lirica: i prossimi appuntamenti della sezione Spectacle della Saison Culturelle 2026/2027
- L’abete di Terranova del Pollino in piazza San Pietro
- News Release – City of Toronto ushers in the 2026-2030 Toronto City Council term
- Agenzia nr. 2187 – Insediamento nuovo Procuratore Aggiunto a Brindisi. Caroli: ‘Ampia disponibilità e massima sinergia con la Commissione
- Antisemitismo, Cecchetti (Lega): Piena solidarietà a Meghnagi e Fadlun. Vili minacce che confermano la necessità della legge
- Agenzia nr. 2186 – Vurchio: “Fare impresa nella Bat deve tornare a essere un’opportunità. Serve una strategia per il territorio
- AGENDA CAMERA DI DOMANI, VENERDÌ 20 NOVEMBRE
- Agenzia nr. 2185 – JTF Taranto. Fischetti: “Altri 4 milioni di euro per la formazione e il reinserimento lavorativo
- MANOVRA Nazionale, ANCE Enna: CAMBIARE NORMA SUPERBONUS PER SALVAGUARDARE LE IMPRESE
- MILLEPROROGHE, ZANGRILLO: “AL LAVORO PER STABILIZZARE PERSONALE ASSUNTO COL PATTO PER NAPOLI, IMPORTANTE INVESTIMENTO IN CAPITALE UMANO”